Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies - PubMed
6 hours ago
- #Alzheimer's disease
- #biomarkers
- #healthcare trends
- Anti-amyloid therapies are changing Alzheimer's disease management, requiring understanding of diagnostic testing and treatment access patterns.
- Following insurance coverage changes, lecanemab infusions increased significantly, reaching 605 in Q1 2025.
- Amyloid PET scans rose, cerebrospinal fluid biomarker orders declined, and plasma p-tau217 orders grew rapidly.
- Females were more likely to be amyloid-beta positive, and APOE-ε4 homozygotes were less likely to start lecanemab.
- The adoption of these therapies led to a swift shift in diagnostic workflows in real-world settings.